News
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
Novo Nordisk A/S (NYSE: NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company highlights early data that shows safety and efficacy figures that are similar to its injectables.
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
MarketBeat on MSN1h
Is It Time to Buy the Dip in Novo Nordisk Stock?CompanyOverview|NYSE:NVO] Despite a double beat in its quarterly earnings on May 7, Novo Nordisk A/S (NYSE: NVO) stock is ...
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk is hedging and building its way around a global tariff war that may threaten the Wegovy maker’s plans to expand ...
Novo Nordisk's (NVO) investors are worried its competition ... Lilly's Zepbound overtook Novo's Wegovy as the leading obesity drug, according to the latest prescription data last month.
People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.
The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback